Conner Mertens 13:29 This episode is made possible with support from AbbVie, sponsor of the Global Healthy Living Foundation
Discontinuation and weight regain How often people stop the medication TRIUMPH-4 (n=445, 68 weeks, obesity with knee osteoarthritis): 18.2% on 12 mg, 12.2% on 9 mg, 4% on placebo 2 TRANSCEND-T2D-1 (n=537, 40 weeks, type 2 diabetes): 5.1% on 12 mg, 4.5% on 9 mg, 0% on placebo 3 Phase 2 (n=338, 48 weeks): 6 to 16% across doses, 1% on placebo 1 For comparison, Wegovys STEP-1 trial reported a discontinuation rate of around 7% due to side effects, and Mounjaros SURMOUNT-1 reported a similar rate
See All Protecting Women & Children We work to protect women & children from predators and abuse while also defending parental rights, personal freedom, and the right to life
Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry
The label for Wegovy includes a warning of the risk of hip fracture: More fractures of the hip and pelvis were reported on WEGOVY than on placebo in female patients: 1% (24/2448) vs
The medication costs the same wholesale price
